Carregant...

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer

Various regimens including molecular targeted agents have been examined in patients with cisplatin (CDDP)-resistant urothelial cancer (UC). However, some studies have been stopped owing to the development of severe adverse events. The main aim of this study was to examine the anticancer effects, cha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Med Oncol
Autors principals: Miyata, Yasuyoshi, Asai, Akihiro, Mitsunari, Kensuke, Matsuo, Tomohiro, Ohba, Kojiro, Sakai, Hideki
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4550651/
https://ncbi.nlm.nih.gov/pubmed/26310889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-015-0683-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!